查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球膀胱過度活動症治療市場
市場調查報告書
商品編碼
1169022

2022-2029 年全球膀胱過度活動症治療市場

Global Overactive Bladder Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期內（2022 年至 2029 年），膀胱過度活動症治療的全球市場規模預計將以 3.6% 的複合年增長率增長。

膀胱過度活動症是一組以膀胱壁突然、不自主的肌肉收縮為特徵的排尿綜合徵。 結果，即使膀胱中只有少量尿液，排尿的衝動也會立即出現並且難以控制。 其他症狀包括夜尿和尿失禁。

市場動態

推動全球膀胱過度活動症治療市場的主要因素包括膀胱過度活動症患病率上升、老年人口增加、神經系統疾病和肥胖症增加、主要市場參與者加大研發力度等。

研發投資的增加和技術進步的不斷增加預計將推動市場的增長。

由於技術進步不斷增加、人口老齡化加劇、研發投資激增、膀胱過度活動症患者數量增加以及新興國家在醫療基礎設施中使用最新技術改進新產品，膀胱過度活動症治療市場正在增長。拖走。

此外，主要的主要市場參與者和製造商不斷投資於新的研發，並增加投資以開發新藥和治療方法，例如具有創新作用機制的神經肌肉阻滯劑。它正在發揮作用。 增加投資和研發將推動市場的增長。 此外，預計主要參與者提供的技術先進的產品也將在市場增長中發揮重要作用。

與這些膀胱過度活動症治療相關的各種新產品發布、研究和提高認識的活動正在促進市場的增長。 例如，2021 年 2 月，艾伯維旗下公司艾爾建（Allergan）宣布其用於不能耐受抗膽鹼能藥物的 5 歲及以上患者的直立性過度活動（膀胱肌）相關神經系統症狀的 BOTOX 宣布獲批。

與膀胱過度活動症治療相關的副作用預計會阻礙市場增長。

使用抗毒蕈鹼藥後會出現一些副作用，例如便秘、口乾、視力模糊、尿路感染、眼睛發癢或乾澀、嗜睡和尿瀦留。 偶爾，人們會出現危及生命的心律失常，但機率非常小。 由於口乾而喝水會加劇膀胱過度活動症的症狀。

認知度不足也是製約市場增長的一大因素。 在低收入國家，人們沒有意識到膀胱過度活動症的流行，缺乏報銷方案阻礙了市場增長。

COVID-19 影響分析

疫情對全球金融預期、運營和危機應對策略產生了積極影響。 COVID-19 的爆發嚴重影響了醫療保健行業。 由於 COVID，膀胱過度活動症治療市場取得了巨大收益。 在 COVID 患者中也觀察到與膀胱相關的問題，例如膀胱過度活動症。 COVID 影響了患者的膀胱。 主要製造商已經啟動了各種研究和臨床試驗。 世界各地正在開展各種舉措、產品發布、合作和合併，推動市場增長。 例如，2022 年 7 月，Urovant Sciences 宣布與 Pierre Fabre Medicament 達成許可協議，在歐洲地區將用於治療膀胱過度活動症的 Vibegron 商業化。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第4章市場動態

  • 市場影響因素
    • 司機
      • 增加研發投資
      • 不斷進步的技術進步
    • 約束因素
      • 與膀胱過度活動症治療相關的副作用
    • 商機
    • 影響分析

第5章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按治療類型分類

  • 神經刺激療法
    • □神經刺激
    • 經皮脛神經刺激療法
  • 行為乾預
    • 骨盆底肌肉鍛煉
    • 健康體重
    • 生物反饋
    • 膀胱訓練
    • 其他
  • 藥物治療
    • 具有抗膽鹼能作用的藥物
      • 奧昔布寧（地托泮）
      • 托特羅定（Detrol）
      • Torspium (Sanctura XR)
      • 非索羅定（託拜厄斯）
      • 索利那新 (Vesicare)
      • 達非那新 (Inaverex)
    • β3 腎上腺素激動劑
      • 米拉貝隆 (milbetriq)
      • Vivegron（Gemtesa）
  • 膀胱肉毒毒素注射
  • 手術
    • 人工括約肌手術
    • 膀胱增大術
    • 括約肌切除術

第 8 章按疾病類型分類

  • 特發性膀胱過度活動症
  • 神經源性膀胱過度活動症

第9章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第10章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第11章公司簡介

  • 美敦力
    • 公司概況
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Astellas Pharma Inc.
  • Teva Pharmaceutical Industries Limited
  • AbbVie Inc.
  • Accord Healthcare Inc.
  • Laborie
  • Macleods Pharmaceuticals Ltd
  • Urovant Sciences

第12章 全球膀胱過度活動症治療市場-DataM

簡介目錄
Product Code: DMPH1214

Market Overview

The global overactive bladder treatment market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 3.6% during the forecast period (2022-2029).

An overactive bladder is a group of urinary syndromes characterized by sudden, involuntary muscle contraction in the wall of the urinary bladder. This results in an immediate, compelling need to urinate that is difficult to suppress, even though the bladder may only contain a small amount of urine. Other symptoms include nocturia or urinary incontinence.

Market Dynamics

The major factors driving the global overactive bladder treatment market are the rise in the prevalence of overactive bladder, growth in the geriatric population, an increase in neurological disorders and obesity, and an increase in R&D by major market players.

The increasing research and development investments and rising technological advancements are expected to drive the market's growth.

The overactive bladder treatment market is driven by rising advancements in technology, an increase in the geriatric population, a surge in research and development investments, an increasing number of overactive bladder patients and improvements in novel products using the latest technology in medical infrastructure in emerging markets.

Furthermore, prominent key market players and manufacturers are continuously working on new research and development and increasing investments to develop new drugs and therapies, such as neuromuscular blocking agents with innovative mechanisms of action. A rise in investment and R&D boost market growth. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market's growth.

Various novel product launches, research studies, and rising awareness initiatives about these Overactive Bladder Treatments contribute to the market's growth. For instance, in February 2021, Allergan, a company of AbbVie, announced the approval of its BOTOX for detrusor overactivity (bladder muscle) related to the neurologic condition in patients aged five years or older who have intolerability to anticholinergic medicines.

Side effects associated with overactive bladder treatments are expected to hamper the market's growth.

Several side effects are observed after using antimuscarinic medicines, such as constipation, dry mouth, blurred vision, urinary tract infection, itchy or dry eyes, drowsiness and urinary retention. Sometimes people experience irregular heart rhythms that can be life-threatening, but their chances are very rare. Drinking water due to dry mouth can aggravate the overactive bladder symptoms.

Lack of awareness is also a leading factor restraining the market's growth. In low-income countries, people are unaware of overactive bladder prevalence, and the unavailability of reimbursement scenarios hinders the market's growth.

COVID-19 Impact Analysis

The pandemic has positively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The overactive bladder treatment market has experienced huge profits due to COVID. In covid patients, bladder-related problems such as overactive bladder were also observed. COVID affected the bladders of patients. Key manufacturers have started various research and clinical trials. Various initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in July 2022, Urovant Sciences announced its license agreement with Pierre Fabre Medicament for Vibegron commercialization for overactive bladder treatment in European Areas.

Segment Analysis

The nerve stimulation segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The nerve stimulation treatment segment is the highest market holder in the global overactive bladder treatment market. The global overactive bladder treatment market is segmented based on treatment type as nerve stimulation, behavioral intervention, medications, botulinum toxin injections and surgery. The nerve stimulation segment is the largest market shareholder due to its inherent advantages over other treatments, increasing technological advancements and novel product launches.

Neuromodulation or nerve stimulation is an effective way to treat an overactive bladder. An electrode is implanted under the skin to stimulate nerves with electricity around the bladder. The electric signals traveling from the bladder to the brain are blocked with electricity reducing the symptoms of an overactive bladder are blocked. These therapies are of two types: sacral neuromodulation and percutaneous tibial nerve stimulation.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in April 2021, Medtronic, the medical technology company, announced receiving approval from the United States Food and Drug Administration to continue the investigational device exemption trial for evaluating its implantable tibial neuromodulation device, an internally developed therapy specially developed for bladder incontinence symptom's relief.

Geographical Analysis

North America holds the largest market share in the global overactive bladder treatment market.

North America dominates the global overactive bladder treatment market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US and the growing geriatric population. The market's significant size is attributed to the high medical expenditure.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of overactive bladder medications and neurostimulation therapies, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region contribute to the overactive bladder treatment market growth.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in Jan 2021, Astellas Phrma Inc. announced its priority review acceptance by the United States Food and Drugs Administration for Mirabegron or Myrbetriq tablets, its novel drug application for neurogenic detrusor overactivity treatment in pediatric patients.

Competitive Landscape

The overactive bladder treatment market is highly competitive with local and global companies' presence. Medtronic, Pfizer Inc., Johnson & Johnson Services, Inc., Astellas Pharma Inc., Teva Pharmaceutical Industries Limited, AbbVie Inc., Accord Healthcare Inc., Laborie, Macleods Pharmaceuticals Ltd, Urovant Sciences and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in November 2022, Urovant Sciences, Sumitovant Biopharma Ltd's subsidiary, announced its partnership with Thinx Inc, an incontinence and period underwear brand. They launched "Time To Go," an educational campaign to educate people about overactive bladders, such as their symptoms and how to manage them.

Medtronic

Overview: Medtronic is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.

Product Portfolio:

Medtronic Bladder Control Therapy: This is a therapy in which the InterStim system delivers sacral neuromodulation. It utilizes an implantable device to deliver electrical pulses to sacral nerves near the tailbone hence creating miscommunication between sacral nerves and the brain to control the symptoms.

Key Development: In February 2022, Medtronic plc, a healthcare technology company, announced that its InterStim X got approved by the United States Food and Drug Administration. This new generation of InterStim recharge-free device is an advanced therapy system to provide sacral neuromodulation therapy for bowel and bladder incontinence,

The global overactive bladder treatment market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing research and development investment
      • 4.1.1.2. Rising technological advancements
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with overactive bladder treatments
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Nerve Stimulation *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Sacral Nerve Stimulation
    • 7.2.4. Percutaneous Tibial Nerve Stimulation
  • 7.3. Behavioural Intervention
    • 7.3.1. Pelvic Floor Muscle Exercise
    • 7.3.2. Healthy weight
    • 7.3.3. Biofeedback
    • 7.3.4. Bladder Training
    • 7.3.5. Others
  • 7.4. Medication
    • 7.4.1. Anticholinergic medications
      • 7.4.1.1. Oxybutynin (Ditropan)
      • 7.4.1.2. Tolterodine (Detrol)
      • 7.4.1.3. Trospium (Sanctura XR)
      • 7.4.1.4. Fesoterodine (Toviaz)
      • 7.4.1.5. Solifenacin (Vesicare)
      • 7.4.1.6. Darifenacin (Enablex)
    • 7.4.2. Beta-3 adrenergic medication
      • 7.4.2.1. Mirabegron (Myrbetriq)
      • 7.4.2.2. Vibegron (Gemtesa)
  • 7.5. Bladder Botulinum Toxin Injections
  • 7.6. Surgery
    • 7.6.1. Artificial Sphincter Surgery
    • 7.6.2. Bladder Augmentation
    • 7.6.3. Sphincter Resection

8. By Disease Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 8.1.2. Market Attractiveness Index, By Disease Type
  • 8.2. Idiopathic Overactive Bladder*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Neurogenic Overactive Bladder

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

10. Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Products Benchmarking
  • 10.4. List of Key Companies to Watch

11. Company Profiles

  • 11.1. Medtronic *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Pfizer Inc.
  • 11.3. Johnson & Johnson Services, Inc.
  • 11.4. Astellas Pharma Inc.
  • 11.5. Teva Pharmaceutical Industries Limited
  • 11.6. AbbVie Inc.
  • 11.7. Accord Healthcare Inc.
  • 11.8. Laborie
  • 11.9. Macleods Pharmaceuticals Ltd
  • 11.10. Urovant Sciences

LIST NOT EXHAUSTIVE

12. Global Overactive Bladder Treatment Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Application
  • 12.3. Contact Us